RECRUITING

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

Talk to us

Conditions

Cushing Syndromedesmopressin, Cushing syndrome, diagnosis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: Cushing syndrome (CS) is a set of diseases that develop when the body produces too much adrenocorticotropic hormone (ACTH). ACTH stimulates the production of a hormone called cortisol. Excess cortisol can cause serious issues, such as diabetes, high blood pressure, weight gain, and mood changes. Diagnosing CS early can be difficult. One test used to diagnose CS, the desmopressin (Desmo) stimulation test (DesmoST), has not been studied in enough people to know how accurate it is. Objective: To find ways to improve the DesmoST. Researchers especially want to learn more about how well the DesmoST identifies people with specific ACTH CSs: Cushing disease (CD) and ectopic ACTH syndrome (EAS). Eligibility: People aged 18 to 70 years who have or may have CS, especially CD or EAS. Healthy volunteers are also needed. Design: Participants with CS will have 3 DesmoSTs at least 48 hours apart. The procedure for each is as follows: They will limit their fluid intake the day before each test. They will have nothing to eat or drink for 12 hours before the test. For 1 of the tests, they will take a pill that contains a hormone (dexamethasone). They will take it around 11 pm the day before the test. Desmo is given through a tube attached to a needle inserted into a vein. Blood will be drawn a total of 6 times before and after the desmo is given. Healthy volunteers will have 4 DesmoSTs. These will be 2 to 14 days apart. All participants will have follow-up visits 3 to 5 days after each test. These visits may be by phone.

Official Title

Phase II Prospective Evaluation of Desmopressin Stimulation Test Performance in ACTH-dependent Cushing s Syndrome

Quick Facts

Study Start:2024-12-09
Study Completion:2029-01-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06635629

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 70 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Aged 18-70 years
  2. * Agreement to adhere to Lifestyle Considerations throughout the study.
  3. * Evidence of acceptable laboratory testing results within four weeks of the first test day, as shown by medical record review:
  4. * Hematocrit at entry \>=33 %
  5. * Plasma sodium 136-145 mmol/L (unless taking a drug that can cause hyponatremia, see below) eGFR \>=60 ml/min/1.73 sq.m, calculated based on serum creatinine
  6. * For subjects taking any drug that could worsen hyponatremia, a normal plasma sodium (136-145 mmol/L) must have been obtained within seven days of the first test day.
  7. * Patients with possible ACTH-dependent Cushing Syndrome (where the results of further work up will classify the patient as having CD, EAS or pseudo-CS):
  8. * Evidence of hypercortisolemia based on at least one screening modality (1 mg dexamethasone suppression test, 24-hour urinary free cortisol (UFC), bedtime or late night (2200h - 2359h) salivary or serum cortisol) within 4 weeks of screening.
  9. * Evidence of normal or increased plasma ACTH (\>20 pg/mL)
  10. * Patients with recurrent ACTH-dependent Cushing Syndrome (previous CD or EAS):
  11. * Healthy volunteers:
  12. * In good general health as evidenced by medical history and physical examination; and in a stable state of health without ongoing acute/temporary illness per the clinical judgement of the investigator.
  1. * Inability to comply with all study procedures and visits
  2. * Inability of subject to understand or to sign a written informed consent document.
  3. * Known allergy/hypersensitivity to desmopressin.
  4. * Pregnancy or lactation, due to alterations in measured serum cortisol and lack of data on desmopressin safety.
  5. * A history of angina, significant coronary artery disease, congestive heart failure, or syndrome of inappropriate antidiuretic hormone secretion (SIADH), due to risk of fluid overload and/or hyponatremia.
  6. * Uncontrolled hypertension (blood pressure \>150/95 mmHg) at screening and before desmopressin administration, due to risk of further increase if fluid overload occurs
  7. * Any condition that in the opinion of the Investigator would jeopardize the participant s appropriate participation in this study.
  8. * Current daily use of any of the following medications:
  9. * Drug used for the stimulation tests: Desmopressin.
  10. * Drugs that can suppress ACTH and cortisol test responses: Systemic glucocorticoids, including inhaled or topical formulations.
  11. * Vasopressors: phenylephrine, dopamine and vasopressin.
  12. * Drugs that interfere with desmopressin duration of action or potency: carbamazepine, lamotrigine, tolvaptan
  13. * Daily use of strong inducers of CYP3A4 (e.g. barbiturates, phenytoin, rifampin, rifabutin, rifapentine, carbamazapine, eslicarbazepine, primidone, cenobamate, Modafinil). Use of St John's wort or nafcillin within 14 days.
  14. * Initiation or dose increase within the past 14 days of drugs that can worsen hyponatremia: non-steroidal anti-inflammatory drugs (NSAIDs), loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide), chlorpromazine, chlorpropamide, cisplatin, monoamine oxidase inhibitors (MAOI), opiate agonists, oxybutynin, selective serotonin reuptake inhibitors (SSRI), vincristine, tricyclic antidepressants (TCAs)
  15. * Chronic enhanced hydration (estimated as \>4 liters) to supplement mealtime fluid intake.
  16. * Any contraindication to intravenous catheter use.
  17. * Previous participation in this protocol.
  18. * History of hemophilia of any type.
  19. * Any hematology or chemistry screening laboratory value drawn at screening that the Investigator determines is clinically significant for exclusion.
  20. * Patients with possible ACTH-dependent Cushing Syndrome:
  21. * Use of medications that block glucocorticoid production or action within the past two weeks-ketoconazole, levoketoconazole, metyrapone, osilodrostat or mifepristone.
  22. * Use of the adrenolytic mitotane at any point, due to its prolonged half-life.
  23. * Use of medications that block ACTH release within the past two weeks - cabergoline, octreotide (subcutaneous), pasireotide (subcutaneous), megestrol acetate, other synthetic glucocorticoids (except for topical or inhaled agents)
  24. * Use of intramuscular long-acting forms of octreotide or pasireotide within the past 4 months.
  25. * Healthy volunteers:
  26. * Use of oral, injectable, or inhaled glucocorticoids (unless intermittent, for symptomatic asthma) within the last year. Use of topical non-hydrocortisone containing potent glucocorticoids on more than 36 square inches in the last six months.

Contacts and Locations

Study Contact

Raven N McGlotten, R.N.
CONTACT
(301) 827-0190
mcglottenr@mail.nih.gov
Lynnette K Nieman, M.D.
CONTACT
(301) 496-8935
niemanl@mail.nih.gov

Principal Investigator

Lynnette K Nieman, M.D.
PRINCIPAL_INVESTIGATOR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Locations (Sites)

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
United States

Collaborators and Investigators

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  • Lynnette K Nieman, M.D., PRINCIPAL_INVESTIGATOR, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-09
Study Completion Date2029-01-01

Study Record Updates

Study Start Date2024-12-09
Study Completion Date2029-01-01

Terms related to this study

Keywords Provided by Researchers

  • desmopressin, Cushing syndrome, diagnosis

Additional Relevant MeSH Terms

  • Cushing Syndrome